Navigating Wegovy Doses: Understanding Availability and Future Pathways

Last reviewed: June 20, 2026

Last updated: June 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Wegovy is currently available in more presentations and more strengths than at any point since it launched, and the premise that its doses are disappearing is out of date. The Wegovy prescribing information (revised 06/2026) lists six single-dose pen strengths, five single-dose syringe strengths, a four-dose single-patient-use pen, and four oral tablet strengths. The shortage years reshaped how people think about GLP-1 supply, but the label is the authoritative statement of what exists — and it now describes a broader product family, a higher labeled maximum dosage, and an oral formulation that did not exist two years ago.

What the Label Currently Lists

Section 3 of the Wegovy label sets out the presentations. Single-dose pens are listed at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, and 7.2 mg, the last designated Wegovy HD. Single-dose syringes are listed at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. There is also a single-patient-use pen described as delivering four doses per pen — the Wegovy FlexTouch, at 9.6 mg/3 mL, providing four 2.4 mg doses. Tablets are listed at 1.5 mg, 4 mg, 9 mg, and 25 mg.

That is a materially different picture from the single-dose-pen-only lineup many readers remember. If you have seen it stated that every Wegovy presentation is a single-dose pen, that description has been overtaken by the current label.

The Labeled Maximum Is Now 7.2 mg

For weight reduction in adults, the label states the maintenance dosage is either 1.7 mg or 2.4 mg once weekly, with 2.4 mg recommended, and adds that "for patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly." The conditional phrasing is the point: 7.2 mg is a ceiling available to some patients, not a stage everyone advances through.

The evidence sits in Study 8, a 72-week trial that enrolled 1,407 adults with obesity and excluded type 2 diabetes, randomized 5:1:1 to 7.2 mg, 2.4 mg, or placebo. Mean baseline weight was 113 kg and mean BMI 39.9 kg/m². At week 72, mean change from baseline was −18.8% at 7.2 mg, −15.5% at 2.4 mg, and −3.9% on placebo — the higher dose beating the standard maintenance dose by 3.3 percentage points. Study 9, in 512 patients with obesity and type 2 diabetes, reported −13.2% at 7.2 mg versus −3.8% on placebo. Discontinuation for adverse reactions ran 5.4% and 5.5% at 7.2 mg in the two trials, versus 1% and 2% on placebo.

Wegovy Tablets Are a Separate Product With a Narrower Label

The tablets are real and they are inside the same prescribing information, but their indication set is smaller than the injection's. Wegovy injection carries four indications: cardiovascular risk reduction in adults with established CV disease and obesity or overweight; weight reduction in adults and pediatric patients aged 12 and older with obesity; weight reduction in adults with overweight plus at least one weight-related comorbid condition; and treatment of noncirrhotic MASH with moderate to advanced fibrosis, granted under accelerated approval.

Wegovy tablets carry two: cardiovascular risk reduction, and weight reduction in adults with obesity or with overweight plus a weight-related comorbid condition. No pediatric indication, no MASH indication. Efficacy was studied in a 64-week trial of 307 patients; the 25 mg tablet produced a mean weight change of −13.6% versus −2.4% on placebo, with 76.3% of patients losing at least 5% of body weight. The label also carries a limitation of use: concomitant use of Wegovy tablets or injection with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended.

Availability: What Actually Changed

The 2023–2024 shortage era is over, and with it the extraordinary regulatory posture that accompanied it. FDA's enforcement discretion for compounded tirzepatide closed on February 18 and March 19, 2025, and for compounded semaglutide on April 22 and May 22, 2025. Compounding now operates under the ordinary statutory framework rather than a shortage-driven exception.

That has a direct bearing on how you should read any claim of "guaranteed availability." Compounded semaglutide is not an FDA-approved product. FDA states that "compounded drugs are not FDA approved" and that "the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed" (FDA). It is a preparation made by a licensed pharmacy pursuant to a prescription for an individual patient — a distinct regulatory category, not a substitute version of the brand and not a generic Wegovy, which does not exist.

Why Presentations Change Over Time

Product lineups shift for reasons unrelated to supply failure. A manufacturer may consolidate around presentations that fit prescribing patterns, retire one device format in favor of another, or add a multi-dose option to reduce sharps volume. New strengths appear when trial data support them, as with the 7.2 mg pen; formulations expand when a different route clears its own trial program, as with the tablets.

The practical consequence for patients is that the presentation you receive may change even when your dosage does not. The label anticipates this, instructing that patients and caregivers be informed which presentation they will receive and be trained for that specific one, and that if the prescribed presentation changes they receive appropriate training and consult the Instructions for Use for the new presentation. Which presentation you get is a prescribing and dispensing decision — your prescriber and your pharmacy label are the only reliable source for what is in your hand.

What "Future Pathways" Should and Should Not Mean

Reasonable planning means knowing the approved options and their evidence, and talking with a prescriber about which fits your clinical picture. It does not mean stockpiling or treating an unapproved research chemical as a fallback. The gap between an FDA-approved product with a published label and a vial bought online is not a pricing gap — it is the entire regulatory apparatus that reviewed safety, effectiveness, and manufacturing quality.

The GLP-1 field is moving quickly, and labels are revised often. The Wegovy label alone has changed substantially inside a single year, adding tablets, adding a higher labeled maximum, and reorganizing its warnings. Anything you read about these products, including this article, should be checked against the current prescribing information before you act on it.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

What Wegovy strengths are currently in the label?

The prescribing information revised 06/2026 lists single-dose pens at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, and 7.2 mg, which is designated Wegovy HD. It lists single-dose syringes at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. It also lists a single-patient-use Wegovy FlexTouch pen at 9.6 mg/3 mL delivering four 2.4 mg doses, plus tablets at 1.5 mg, 4 mg, 9 mg, and 25 mg.

Is 7.2 mg the standard Wegovy dose now?

No. The label states the maintenance dosage for weight reduction in adults is either 1.7 mg or 2.4 mg once weekly, with 2.4 mg recommended. It describes 7.2 mg as a maximum available for patients who tolerate 2.4 mg for at least four weeks and for whom additional weight reduction is clinically indicated. In Study 8, mean weight change at week 72 was −18.8% at 7.2 mg versus −15.5% at 2.4 mg and −3.9% on placebo.

Are Wegovy tablets the same as the injection?

They share an active ingredient and a prescribing information document, but they are distinct products with distinct indication sets. The injection carries four indications, including a pediatric weight-reduction indication for ages 12 and older and an accelerated approval for noncirrhotic MASH with moderate to advanced fibrosis. The tablets carry two: cardiovascular risk reduction and weight reduction in adults. The label also advises against combining semaglutide products.

Is Wegovy still in shortage?

The shortage period that shaped 2023 and 2024 has ended, and the FDA enforcement-discretion windows that accompanied it closed during 2025 — February 18 and March 19 for compounded tirzepatide, and April 22 and May 22 for compounded semaglutide. Supply questions specific to your prescription are best answered by your dispensing pharmacy, since availability varies by presentation, by wholesaler, and by location at any given time.

Is compounded semaglutide an equivalent backup if a dose is unavailable?

It is not an equivalent product. The FDA states that compounded drugs are not FDA approved and that the agency does not review them for safety, effectiveness, or quality before marketing. There is no approved generic version of Wegovy. A compounded preparation is made by a licensed pharmacy pursuant to a prescription for an individual patient, which is a different regulatory category from an approved finished drug product.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.